Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis.

Gass K, Beau de Rochars MV, Boakye D, Bradley M, Fischer PU, Gyapong J, Itoh M, Ituaso-Conway N, Joseph H, Kyelem D, Laney SJ, Legrand AM, Liyanage TS, Melrose W, Mohammed K, Pilotte N, Ottesen EA, Plichart C, Ramaiah K, Rao RU, Talbot J, Weil GJ, Williams SA, Won KY, Lammie P.

PLoS Negl Trop Dis. 2012 Jan;6(1):e1479. doi: 10.1371/journal.pntd.0001479. Epub 2012 Jan 17.

2.

Tools to support policy decisions related to treatment strategies and surveillance of Schistosomiasis japonica towards elimination.

Zhou XN, Xu J, Chen HG, Wang TP, Huang XB, Lin DD, Wang QZ, Tang L, Guo JG, Wu XH, Feng T, Chen JX, Guo J, Chen SH, Li H, Wu ZD, Peeling RW.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1408. doi: 10.1371/journal.pntd.0001408. Epub 2011 Dec 20.

3.

Can clinical signs of trachoma be used after multiple rounds of mass antibiotic treatment to indicate infection?

Munoz B, Stare D, Mkocha H, Gaydos C, Quinn T, West SK.

Invest Ophthalmol Vis Sci. 2011 Nov 11;52(12):8806-10. doi: 10.1167/iovs.11-8074.

4.

Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis.

Moss DM, Priest JW, Boyd A, Weinkopff T, Kucerova Z, Beach MJ, Lammie PJ.

Am J Trop Med Hyg. 2011 Aug;85(2):229-37. doi: 10.4269/ajtmh.2011.11-0029.

5.

What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting.

Burton MJ, Hu VH, Massae P, Burr SE, Chevallier C, Afwamba IA, Courtright P, Weiss HA, Mabey DC, Bailey RL.

Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):6012-7. doi: 10.1167/iovs.11-7326.

6.

How reliable are tests for trachoma?--a latent class approach.

See CW, Alemayehu W, Melese M, Zhou Z, Porco TC, Shiboski S, Gaynor BD, Eng J, Keenan JD, Lietman TM.

Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6133-7. doi: 10.1167/iovs.11-7419.

7.

Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.

Stare D, Harding-Esch E, Munoz B, Bailey R, Mabey D, Holland M, Gaydos C, West S.

Ophthalmic Epidemiol. 2011 Feb;18(1):20-9. doi: 10.3109/09286586.2010.545500.

PMID:
21275593
8.

Mass treatment with azithromycin for trachoma control: participation clusters in households.

Ssemanda EN, Munoz B, Harding-Esch EM, Edwards T, Mkocha H, Bailey RL, Sillah A, Stare D, Mabey DC, West SK; PRET Project Team.

PLoS Negl Trop Dis. 2010 Oct 5;4(10). pii: e838. doi: 10.1371/journal.pntd.0000838.

9.

A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans.

Wang J, Zhang Y, Lu C, Lei L, Yu P, Zhong G.

J Immunol. 2010 Aug 1;185(3):1670-80. doi: 10.4049/jimmunol.1001240. Epub 2010 Jun 25.

10.

Diagnostic value of an enzyme-linked immunosorbent assay using the recombinant CT694 species-specific protein of Chlamydia trachomatis.

Frikha-Gargouri O, Gdoura R, Znazen A, Gargouri J, Rebai A, Hammami A.

J Appl Microbiol. 2009 Dec 1;107(6):1875-82. doi: 10.1111/j.1365-2672.2009.04365.x. Epub 2009 May 5.

11.

Evidence that CT694 is a novel Chlamydia trachomatis T3S substrate capable of functioning during invasion or early cycle development.

Hower S, Wolf K, Fields KA.

Mol Microbiol. 2009 Jun;72(6):1423-37. doi: 10.1111/j.1365-2958.2009.06732.x. Epub 2009 May 15.

12.

Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection.

Wills GS, Horner PJ, Reynolds R, Johnson AM, Muir DA, Brown DW, Winston A, Broadbent AJ, Parker D, McClure MO.

Clin Vaccine Immunol. 2009 Jun;16(6):835-43. doi: 10.1128/CVI.00021-09. Epub 2009 Apr 8.

13.

Trachoma: global magnitude of a preventable cause of blindness.

Mariotti SP, Pascolini D, Rose-Nussbaumer J.

Br J Ophthalmol. 2009 May;93(5):563-8. doi: 10.1136/bjo.2008.148494. Epub 2008 Dec 19. Review.

PMID:
19098034
14.

Diagnosis and assessment of trachoma.

Solomon AW, Peeling RW, Foster A, Mabey DC.

Clin Microbiol Rev. 2004 Oct;17(4):982-1011, table of contents. Review.

15.

Chlamydia trachomatis and Chlamydia pneumoniae infections in children and adolescents.

Hammerschlag MR.

Pediatr Rev. 2004 Feb;25(2):43-51. Review. No abstract available.

PMID:
14754926
16.

Mucosal and systemic immune responses to plasmid protein pgp3 in patients with genital and ocular Chlamydia trachomatis infection.

Ghaem-Maghami S, Ratti G, Ghaem-Maghami M, Comanducci M, Hay PE, Bailey RL, Mabey DC, Whittle HC, Ward ME, Lewis DJ.

Clin Exp Immunol. 2003 Jun;132(3):436-42.

17.

Estimating the burden and economic impact of trachomatous visual loss.

Frick KD, Basilion EV, Hanson CL, Colchero MA.

Ophthalmic Epidemiol. 2003 Apr;10(2):121-32.

PMID:
12660860
18.

A simplified cataract grading system.

Thylefors B, Chylack LT Jr, Konyama K, Sasaki K, Sperduto R, Taylor HR, West S; WHO Cataract Grading Group.

Ophthalmic Epidemiol. 2002 Apr;9(2):83-95.

PMID:
11821974
19.
20.

Detection of Chlamydia trachomatis-specific antibodies in human sera by recombinant major outer-membrane protein polyantigens.

Mygind P, Christiansen G, Persson K, Birkelund S.

J Med Microbiol. 2000 May;49(5):457-65.

PMID:
10798559

Supplemental Content

Support Center